Karyopharm Therapeutics Inc.
KPTI · Healthcare · $28M
After-hours $1.25+3.73%
Price
$9.55
$1.21
Jul 1, 26Sep 29, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
9/'26
Revenue$34M+0.3%
6/'26 vs prev quarter
Company Health
Market Cap$28M
Operating Margin-56.2%
Cash on Hand$65M230.8% of market cap
Free Cash Flow$-65M-231.6% of market cap
Among 326 Biotechnology peers
LowMedianHigh
PSR0.2xmedian 11.1xROE+68.1%median -54.5%Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Sep 1
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with MyelofibrosisAug 31
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with MyelofibrosisAug 31
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTIAug 27
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTIAug 25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTIAug 20
